Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN6051 monotherapy and combination with pembrolizumab in advanced malignancy
NCT04694781Phase 1Completed
- Sponsor
- Lijin Biomedical Technology
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of exlinkibart in advanced cancer and malignancy (4 arms), sponsored by Lijin Biomedical Technology. Primary endpoints: Treatment-emergent adverse events at 24 months and Maximum Tolerated Dose / Recommended Dose for Expansion / Recommended Phase 2 Dose at 24 months. Started May 2021; status: completed.
02
Drugs
exlinkibart
03
Conditions
advanced cancermalignancy
Beyond the preview
Go deeper on NCT04694781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694781.